Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00551460 · ClinicalTrials.gov registry record · Phase 2
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00551460 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 78 participants.
The verdict
NCT00551460, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Gemtuzumab may also stop the growth of promyelocytic leukemia by blocking blood flow to the cancer. Giving gemtuzumab together with combination chemotherapy may be more effective in treating promyelocytic leukemia. PURPOSE: This phase II trial is studying how well giving gemtuzumab together with combination chemotherapy works in treating patients with previously untreated promyelocytic leukemia.
Interventions
- DRUG mercaptopurine
- DRUG methotrexate
- DRUG gemtuzumab ozogamicin
- DRUG tretinoin
- DRUG arsenic trioxide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2007-11-15 |
| Est. Completion | 2018-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00551460
The ClinicalTrials.gov registry entry for NCT00551460 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mercaptopurine is the first listed.
NCT00551460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00551460 about?
NCT00551460 is a clinical study titled "S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as gemtuzumab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry can...
What is the current status of trial NCT00551460?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2007-11-15. Estimated completion is 2018-02-05.
What interventions are being tested in trial NCT00551460?
The interventions under investigation include: mercaptopurine (DRUG), methotrexate (DRUG), gemtuzumab ozogamicin (DRUG), tretinoin (DRUG), arsenic trioxide (DRUG).
Who is sponsoring clinical trial NCT00551460?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.